A 26-year-old female with social anxiety disorder was started on sertraline 100 mg daily twelve weeks ago. Her baseline Liebowitz Social Anxiety Scale (LSAS) total score was 88 and she avoided most social interactions including work meetings, eating in public, and speaking with unfamiliar people. At today's evaluation, her LSAS total score is 62 and she reports attending some work meetings with moderate anxiety but can participate when directly asked questions. She still avoids eating in restaurants and declines social invitations from coworkers. She reports sertraline has reduced the intensity of anticipatory anxiety and physical symptoms such as trembling and blushing, but she has not been able to translate this symptom reduction into meaningful behavioral change outside of mandatory work situations. She denies medication side effects. The PMHNP is evaluating the treatment response and determining next steps. Which of the following best represents the appropriate evaluation?